IOB - Delayed Quote USD

Johnson & Johnson (0R34.IL)

Compare
143.00
+0.70
+(0.49%)
At close: January 10 at 7:14:46 PM GMT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
87,696,000.00
85,159,000.00
79,990,000.00
78,740,000.00
82,584,000.00
Cost of Revenue
27,141,000.00
26,553,000.00
24,596,000.00
23,402,000.00
28,427,000.00
Gross Profit
60,555,000.00
58,606,000.00
55,394,000.00
55,338,000.00
54,157,000.00
Operating Expense
37,640,000.00
35,197,000.00
33,181,000.00
34,395,000.00
34,424,000.00
Operating Income
22,915,000.00
23,409,000.00
22,213,000.00
20,943,000.00
19,733,000.00
Net Non Operating Interest Income Expense
645,000.00
489,000.00
214,000.00
-130,000.00
-90,000.00
Other Income Expense
-5,990,000.00
-8,802,000.00
-3,058,000.00
-1,635,000.00
-3,146,000.00
Pretax Income
17,626,000.00
15,062,000.00
19,359,000.00
19,178,000.00
16,497,000.00
Tax Provision
2,859,000.00
1,736,000.00
2,989,000.00
1,377,000.00
1,783,000.00
Net Income Common Stockholders
14,684,000.00
35,153,000.00
17,941,000.00
20,878,000.00
14,714,000.00
Diluted NI Available to Com Stockholders
14,684,000.00
35,153,000.00
17,941,000.00
20,878,000.00
14,714,000.00
Basic EPS
6.22
13.88
6.83
7.93
5.59
Diluted EPS
6.15
13.72
6.73
7.81
5.51
Basic Average Shares
2,407,350.00
2,533,500.00
2,625,200.00
2,632,100.00
2,632,800.00
Diluted Average Shares
2,429,975.00
2,560,400.00
2,663,900.00
2,674,000.00
2,670,700.00
Total Expenses
64,781,000.00
61,750,000.00
57,777,000.00
57,797,000.00
62,851,000.00
Net Income from Continuing & Discontinued Operation
14,684,000.00
35,153,000.00
17,941,000.00
20,878,000.00
14,714,000.00
Normalized Income
20,790,756.38
21,292,770.00
19,380,068.00
18,830,152.00
14,934,324.00
Interest Income
1,414,000.00
1,261,000.00
490,000.00
53,000.00
111,000.00
Interest Expense
769,000.00
772,000.00
276,000.00
183,000.00
201,000.00
Net Interest Income
645,000.00
489,000.00
214,000.00
-130,000.00
-90,000.00
EBIT
18,395,000.00
15,834,000.00
19,635,000.00
19,361,000.00
16,698,000.00
EBITDA
25,681,000.00
23,320,000.00
26,605,000.00
26,751,000.00
23,929,000.00
Reconciled Cost of Revenue
27,141,000.00
26,553,000.00
24,596,000.00
23,402,000.00
28,427,000.00
Reconciled Depreciation
7,286,000.00
7,486,000.00
6,970,000.00
7,390,000.00
7,231,000.00
Net Income from Continuing Operation Net Minority Interest
14,767,000.00
13,326,000.00
16,370,000.00
17,801,000.00
14,714,000.00
Total Unusual Items Excluding Goodwill
-7,190,000.00
-9,002,000.00
-3,558,000.00
-1,109,000.00
-247,000.00
Total Unusual Items
-7,190,000.00
-9,002,000.00
-3,558,000.00
-1,109,000.00
-247,000.00
Normalized EBITDA
32,871,000.00
32,322,000.00
30,163,000.00
27,860,000.00
24,176,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-1,166,243.62
-1,035,230.00
-547,932.00
-79,848.00
-26,676.00
12/31/2020 - 11/5/2014

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

600666.SS Aurora Optoelectronics Co.,Ltd.
2.1900
-5.19%
 
6MK.F Merck & Co., Inc.
96.80
-0.31%
 
AMGN.BA Amgen Inc.
10,375.00
-2.81%
 
PFE.DU Pfizer Inc
26.32
+1.08%
 
ZEG.F AstraZeneca PLC
131.35
-0.61%
 
SNW.HM Sanofi SA
95.59
-0.93%
 
NOTA.DU Novartis AG
96.80
0.00%
 
IDP.HM Biogen Inc
144.65
-0.38%
 
RHO6.SG Roche Holding AG
35.41
+0.69%
 
NOTA.SG Novartis AG
96.80
-0.21%